Abstract:e14574 Background: Immune checkpoint inhibitors (ICIs), targeting the programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1) or cytotoxic T lymphocyte-associated protein 4 (CTLA-4) have demonstrated impressive anti-tumor efficacy in multiple tumors, particularly non-small cell lung cancer (NSCLC). However, only a minority of patients could clinically benefit from the ICIs. Therefore, it is of vital clinical significance to explore underlying predictive biomarkers to identify to identify these most potentially ICIs-benefitable patients. Nuclear pore associated protein 1 ( NPAP1 ) encodes an protein is associated with the nuclear pore complex and has been previously reported as a potential prognostic biomarker for laryngeal, colorectal and lung cancers. However, its role in lung cancer immunotherapy remains unknown. Here we aimed to explore the association between NPAP1 and ICIs. Methods: 165 NSCLC patients from three public immunotherapy cohorts (Hellmann 2018, Miao 2018, and Rizvi 2015 cohort) were included to analyze the association between NPAP1 gene mutation and efficacy of ICI therapy. Genomic, survival and mRNA data of NSCLC patients from the Cancer Genome Atlas (TCGA) database was used to explore the potential mechanisms of anti-tumor immunity. Results: NSCLC patients with NPAP1 mutation were significantly associated with better PFS (HR = 0.37; 95% CI, 0.19-0.71; P = 0.002), objective response rate (ORR, 54.2% vs 28.4%; P = 0.048) and durable clinical benefit (DCB, 75.0% vs 42.6%; P = 0.003) after ICIs therapy, compared with those with wide-type NPAP1 . NPAP1 mutation were associated with increased TMB ( P < 0.001). In the multivariable Cox proportional hazards regression model adjusted by smoking status, PD-L1 expression and TMB, the association between NPAP1 mutation and PFS remained significant (HR = 0.46; 95% CI, 0.23-0.92; P = 0.028). In contrast, no association between NPAP1 mutation and OS (LUAD: P = 0.24 ; LUSC: P = 0.94) or PFS (LUAD: P = 0.3; LUSC: P = 0.72) was observed in TCGA datasets, suggesting that NPAP1 mutation may be a predictive but not a prognostic factor in ICI treatment for NSCLC patients. Based on CIBERSORT-inferred tumor infiltrating lymphocytes from TCGA, NPAP1 mutation was significantly associated with higher activated memory CD4+ T cell and CD8+ T cell. Moreover, NPAP1 mutation was associated with increased TMB ( P < 0.001) and neoantigen load ( P < 0.001) in TCGA. Conclusions: Our results demonstrated that NPAP1 mutation is an underlying classifier that could stratify patients with NSCLC for ICIs. The role of NPAP1 in immunotherapy is needed to be further studied.

BAP1 is a Good Prognostic Factor in Advanced Non-Small Cell Lung Cancer.

EP1.03-17 Outcomes of Molecular Characteristics in Chinese BAP1-Mutant Non-Small Cell Lung Cancer Patients

BRCA1-associated protein 1 deficiency in lung adenocarcinoma predicts poor outcome and increased tumor invasion

Pan-cancer Analysis of the Prognostic and Immunological Role of BRCA1-associated Protein 1 Gene (BAP1): Friend or Foe?

Cytoplasmic Expression of BAP1 As an Independent Prognostic Biomarker for Patients with Gliomas.

Tissue-specific Significance of BAP1 Gene Mutation in Prognostic Prediction and Molecular Taxonomy among Different Types of Cancer.

Prognostic significance of BRCA1-associated protein 1 in colorectal cancer

Decreased Expression of BRCA1-associated Protein 1 Predicts Unfavorable Survival in Gastric Adenocarcinoma

BAP1 Acts As a Tumor Suppressor in Intrahepatic Cholangiocarcinoma by Modulating the ERK1/2 and JNK/c-Jun Pathways.

Loss of BAP1 Results in Growth Inhibition and Enhances Mesenchymal-Epithelial Transition in Kidney Tumor Cells.

NPAP1 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC.

Somatic mutation and expression of BAP1 in hepatocellular carcinoma: an indicator for ferroptosis and immune checkpoint inhibitor therapies

B-Cell Receptor-Associated Protein 31 Promotes Metastasis Via AKT/β-Catenin/Snail Pathway in Hepatocellular Carcinoma

Common, Germline Genetic Variations in the Novel Tumor Suppressor Bap1 and Risk of Developing Different Types of Cancer

Increased Expression of TAP is Predictive of Poor Prognosis in Patients with Non-Small Cell Lung Cancer

EZH2 Expression is Increased in BAP1-mutant Renal Clear Cell Carcinoma and is Related to Poor Prognosis

BAP31 promotes breast cancer progression by interaction with SERCA2

BAP1 loss confers sensitivity to bromodomain and extra-terminal inhibitors in renal cell carcinoma

Comprehensive Analysis of BAP1 Somatic Mutation in Clear Cell Renal Cell Carcinoma to Explore Potential Mechanisms in Silico

BAP31 is Frequently Overexpressed in Patients with Primary Colorectal Cancer and Correlates with Better Prognosis

Prediction of Survival Prognosis of Non-Small Cell Lung Cancer by APE1 Through Regulation of Epithelial-Mesenchymal Transition